The CNMI stands to receive some $10,000 from two U.S. drug manufacturers in a settlement of a federal law enforcement action that accused the companies of antitrust violations that resulted in the destruction of market competition of a certain over-the-counter generic brand.<\/p>\n
In a media statement, Attorney General Pamela Brown disclosed that the CNMI, along with 49 other U.S. states and territories, reached a settlement with Perrigo and Alpharma.<\/p>\n
The two companies are the only Federal Drug Administration-approved manufacturers of the generic over-the-counter liquid suspension Ibufropen, a drug product used to temporarily reduce fever and relieve minor aches and pains in children.<\/p>\n
\u201cThe states allege that, in 1998, Perrigo and Alpharma entered into an agreement that gave Perrigo 100-percent of the market for generic versions of this product. The states further allege that Alpharma never began selling its generic product, and that Perrigo captured a 100-percent share of the market,\u201d the media release stated.<\/p>\n
\u201cThe lack of competition caused retail stores that sell store brand products to pay more for this product than they would have paid in a competitive market,\u201d the AGO explained.<\/p>\n
The connivance destroyed market competition in the sale of the generic brand Children\u2019s Motrin. The AGO clarified the product is different from Motrin, a registered trademark of Johnson & Johnson, which was not a party to the case.<\/p>\n
The antitrust violations cropped up after joint investigations conducted by certain states and the Federal Trade Commission. The AGO said the U.S. District Court of Columbia approved the settlement.<\/p>\n
Besides agreeing to pay the CNMI some $10,000, the drug companies would pay approximately $1 million to funds administered by the National Association of Attorneys General to help support future antitrust enforcement actions.<\/p>\n","protected":false},"excerpt":{"rendered":"
The CNMI stands to receive some $10,000 from two U.S. drug manufacturers in a settlement of a federal law enforcement action that accused the companies of antitrust violations that resulted in the destruction of market competition of a certain over-the-counter generic brand.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-83795","post","type-post","status-publish","format-standard","hentry","category-local-news"],"_links":{"self":[{"href":"https:\/\/www.saipantribune.com\/index.php\/wp-json\/wp\/v2\/posts\/83795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.saipantribune.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.saipantribune.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.saipantribune.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.saipantribune.com\/index.php\/wp-json\/wp\/v2\/comments?post=83795"}],"version-history":[{"count":0,"href":"https:\/\/www.saipantribune.com\/index.php\/wp-json\/wp\/v2\/posts\/83795\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.saipantribune.com\/index.php\/wp-json\/wp\/v2\/media?parent=83795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.saipantribune.com\/index.php\/wp-json\/wp\/v2\/categories?post=83795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.saipantribune.com\/index.php\/wp-json\/wp\/v2\/tags?post=83795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}